Safety and Efficacy of Two Oral Tinidazole Regimens for Refractory Trichomonas Vaginitis

Launched by SHANGRONG FAN · May 19, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of two different treatment plans using an oral medication called tinidazole for women who have a persistent infection known as trichomonas vaginitis. This condition can cause uncomfortable symptoms, and the trial aims to find out if these new treatment options can help women who haven’t responded to standard treatments.

To participate in this trial, women need to be at least 18 years old and should have already tried the usual treatment for this infection, which did not work for them. However, women who are pregnant, breastfeeding, have allergies to certain medications, or have serious health issues like HIV will not be eligible. If selected, participants can expect to receive one of the two tinidazole regimens and will be monitored for their safety and how well the treatment works. This trial is an important step in finding better options for women struggling with this condition.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women be at least 18 years of age
• • Failure of conventional treatment (recommended by guidelines including tinidazole, 2g once daily for 5-7 days)
• Exclusion Criteria:
• • Allergy to metronidazole or tinidazol
• • Pregnant or nursing
• • HIV or other chronic disease